AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02467400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00252915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF (verum)
Description: sagramostim
Study NCT04250220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: e-Health based strategy: PPG-based screening using a smartphone and ECG patch
Description: PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
Study NCT02468674 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimagrumab
Description: bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Study NCT03686865 — intervention group
Intervention type: DEVICE
Intervention: dental implants
Description: extraction sockets regenerated with xenograft
Study NCT03350178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transfer
Description: transfer of fecal microbiota from healthy donor to the patients
Study NCT00101491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication DVD video
Description: Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
Study NCT00101491 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Communication DVD video
Description: Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
Study NCT00713063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: 12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
Study NCT00713063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: 12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
Study NCT02967458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere Intravenous Suspension
Description: The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
Study NCT01914913 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BMMNCs
Description: Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
Study NCT03664401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis Oral™
Study NCT03664401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: A free gingival autograft from patient palate placed and secured on wound bed
Study NCT00941889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5 ml
Study NCT00941889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Description: 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
Study NCT01122030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Tablets or solution for oral administration
Study NCT01122030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets or solution for oral administration
Study NCT01471860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO System
Study NCT01471860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Management
Study NCT02590887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink manufactured from lupine peptides
Description: Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
Study NCT02729948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02729948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endoscope
Description: Undergo TCE
Study NCT00630812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled mannitol
Description: 400 mg BD for 26 + 26 weeks
Study NCT00630812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
Study NCT02387619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
Study NCT02387619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
Study NCT02387619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
Study NCT02694211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProMES
Description: Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
Study NCT02927873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) low dose formulation vaccine
Description: 2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study NCT02927873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) middle dose formulation vaccine
Description: 2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study NCT02468674 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Study NCT02145780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2g of grape polyphenol extract
Description: Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
Study NCT04211142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)
Description: Laparoscopic inguinal hernia repair
Study NCT02927873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) high dose formulation vaccine
Description: 2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study NCT04211142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Inguinal Hernia Repair (Lichtenstein repair)
Description: Open Inguinal Hernia Repair
Study NCT03500042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory pressure threshold device
Description: The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
Study NCT03088618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal septoplasty
Description: Type of surgery
Study NCT04082728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole
Description: Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
Study NCT04082728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
Study NCT02264093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Study NCT02264093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT02264093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talsaclidine
Study NCT02927873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study NCT02264093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine
Study NCT03195062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Liquid test meal (fructose+glucose)
Study NCT01766817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020
Study NCT01766817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-986020
Study NCT03472235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedle
Description: TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session.
Study NCT02035150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oatmeal
Description: A breakfast consisting of oatmeal
Study NCT02035150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Frosted Flakes
Description: A breakfast consisting of Frosted Flakes and milk
Study NCT02035150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Breakfast
Description: A breakfast consisting of plain water
Study NCT02145780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: 2g of placebo (lactose)
Description: Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
Study NCT02998424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Continuous infusion
Study NCT03924453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pearl Powered by Proov
Description: Participants self test in their homes and report back data via uploading onto an app and taking surveys.
Study NCT04579276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Intrathoracic method undergone through video assisted surgery (VATS
Study NCT04579276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural analgesia
Description: locoregional analgesia under ultrasound control
Study NCT02318147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT by retention enema with fresh bacteria from healthy donor
Study NCT02318147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The traditional treatment
Description: the traditional treatments according to associated guidelines
Study NCT04064866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High yield pure PRP
Description: The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample.
Study NCT04064866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
Study NCT04064866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProPlaz PPC
Description: Trademarked name of an FDA-cleared product
Study NCT03780686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine, dopamine
Description: drugs to decrease bleeding
Study NCT03093818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing
Description: The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex).
Study NCT03188718 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: WatchPAT Intervention
Description: Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
Study NCT00886041 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopy
Description: subjected to laparoscopy
Study NCT00886041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ovarian stimulation
Description: ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
Study NCT01144728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE + METFORMIN
Description: Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
Study NCT02318147 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: The traditional treatment
Description: the traditional treatments according to associated guidelines
Study NCT01304693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
Study NCT01304693 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg
Description: Administered as a single intravitreal injection
Study NCT03648034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: To perform scalp nerve blocks with ropivacaine
Study NCT03648034 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: To perform scalp nerve blocks with saline
Study NCT00865514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
Study NCT00865514 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: Subjects will have 5 mls of blood drawn for genotyping
Study NCT00865514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leucine
Description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
Study NCT00865514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tyrosine
Description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
Study NCT00542789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg once daily oral
Study NCT00542789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily oral
Study NCT01941758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Study NCT02622191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral domain Optical Coherence Tomography
Description: Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
Study NCT02963792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Professionals burnout
Study NCT00690105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus 0.1%
Description: ointment
Study NCT00690105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone 0.005 %
Description: ointment
Study NCT00106938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid artery stenting with filter (interventional)
Description: Carotid artery stenting with filter (interventional)
Study NCT01941758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03595852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
Study NCT03595852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV normal saline will be given to patients 30-60 minutes prior to incision
Study NCT01153880 — intervention group
Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription sales claim of retapamulin
Study NCT01153880 — intervention group
Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescription sales claims for retapamulin and topical mupirocin